Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring the Role of Long Non-Coding RNAs in Mediating Cisplatin Resistance in Glioma/Glioblastoma Cells.

International journal of molecular sciences·2026
Same author

The Association Between Serum α-Tocopherol and Pathogenesis of Multiple Sclerosis: A Systematic Review and Meta-Analysis of Case-Control Studies.

BioMed research international·2026
Same author

Beyond "student-led": Toward an entrustment framework for faculty involvement in student-led OSCEs.

Medical teacher·2026
Same author

Effects of Livergol and Hydroalcoholic Extracts of Barberry, Jujube, and Flixweed on Oxidative Stress and Inflammatory Gene Expression in a MASLD Animal Model.

Mediators of inflammation·2026
Same author

Artificial Intelligence and Robotics in General Surgery: Opportunities and Challenges.

Cureus·2026
Same author

The emerging role of the meningeal lymphatic and glymphatic systems in migraine pathophysiology: a systematic review.

The journal of headache and pain·2026

Related Experiment Video

Updated: Jun 9, 2026

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS

Published on: December 26, 2015

17.3K

Coenzyme Q10 supplementation in multiple sclerosis; A systematic review.

Shabnam Salekzamani1, Sina Pakkhesal2, Mohammad Babaei2

  • 1Department of Nutrition, Faculty of Health and Nutrition, Bushehr University of Medical Sciences, Bushehr, Iran.

Multiple Sclerosis and Related Disorders
|December 12, 2024
PubMed
Summary

Coenzyme Q10 (CoQ10) supplementation may improve oxidative stress and inflammation in Multiple Sclerosis (MS) patients. A higher dose of 500mg/day showed benefits for fatigue and depression, unlike lower doses.

Keywords:
Coenzyme Q10Multiple sclerosissystematic review

More Related Videos

Quantification of Coenzyme A in Cells and Tissues
08:51

Quantification of Coenzyme A in Cells and Tissues

Published on: September 27, 2019

8.3K
Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
07:35

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Published on: June 1, 2022

2.2K

Related Experiment Videos

Last Updated: Jun 9, 2026

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS

Published on: December 26, 2015

17.3K
Quantification of Coenzyme A in Cells and Tissues
08:51

Quantification of Coenzyme A in Cells and Tissues

Published on: September 27, 2019

8.3K
Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
07:35

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Published on: June 1, 2022

2.2K

Area of Science:

  • Neuroscience
  • Immunology
  • Biochemistry

Background:

  • Multiple Sclerosis (MS) is a chronic, progressive CNS inflammatory disease.
  • Oxidative stress is a key factor in MS pathogenesis.
  • Coenzyme Q10 (CoQ10) is a mitochondrial antioxidant vital for ATP production.

Purpose of the Study:

  • To systematically review CoQ10 supplementation effects on oxidative stress, inflammation, and clinical status in MS patients.
  • To assess dose-dependent outcomes of CoQ10 in MS.

Main Methods:

  • Systematic review adhering to Cochrane and PRISMA guidelines.
  • Searched PubMed, Scopus, Embase, and Web of Science.
  • Assessed risk of bias using the revised Cochrane RoB2 tool.

Main Results:

  • Included 6 studies (195 participants), comprising 3 RCTs, 2 semi-experimental, and 1 retrospective analysis.
  • 200mg/day CoQ10 showed controversial effects on inflammatory factors and lipid peroxidation.
  • 500mg/day CoQ10 improved oxidative stress, inflammation, depression, and fatigue in MS patients.

Conclusions:

  • CoQ10 exhibits dose-dependent benefits in reducing MS-related oxidative stress and inflammation.
  • CoQ10 may alleviate clinical symptoms like fatigue and depression in MS.
  • Further research is recommended due to limited study numbers and evidence.